Application of Classic Utilities to Published Pediatric Cost-Utility Studies

被引:10
|
作者
Finnell, S. Maria E. [1 ,3 ]
Carroll, Aaron E. [1 ,2 ,3 ]
Downs, Stephen M. [1 ,2 ,3 ]
机构
[1] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA
[2] Ctr Hlth Policy & Professionalism Res, Indianapolis, IN USA
[3] Regenstrief Inst Healthcare, Indianapolis, IN USA
关键词
cost effectiveness; cost-utility analysis; quality-adjusted life years; utility; child; cost benefit analysis; INTRATHECAL BACLOFEN THERAPY; QUALITY-OF-LIFE; ROTAVIRUS VACCINATION; CHILDHOOD IMMUNIZATION; THRESHOLD RETINOPATHY; INFANT VACCINATION; CHILDREN; HEALTH; IMPACT; CARE;
D O I
10.1016/j.acap.2011.09.003
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
OBJECTIVE: Economic analyses, such as cost-utility analyses (CUAs), are dependent on the quality of the data used. Our objective was to test how health utility values (measurements of patient preference) assessed by recommended methods (classic utilities) would impact the conclusions in published pediatric CUAs. METHODS: Classic utilities for pediatric health states were obtained by recommended utility assessment methods, time trade-off, and standard gamble in 4016 parent interviews. To test the impact of these utilities on published studies, we obtained a sample of published pediatric CUAs by searching Medline, EMBASE, EconLit, Health Technology Assessment Database, Cochrane Database on Systematic Reviews, Database of Abstracts of Reviews of Effects, and the Cost Effective Analysis (CEA) Registry at Tufts Medical Center, using search terms for cost-utility analysis. Articles were included when results were presented as cost per quality adjusted life-years (QALYs), the interventions were for children <18 years of age and included at least one of the following health states: attention deficit hyperactivity disorder, asthma, gastroenteritis, hearing loss, mental retardation, otitis media, seizure disorder, or vision loss. Studies that did not include these or equivalent health states were excluded. For each CUA, we determined utilities (values for patient preference), the utility assessment method used, and presence of one-way sensitivity analyses (SAs) on utilities. When one-way SAs were conducted, we determined if using our classic utilities would change the result of the CUA. When an SA was not presented, we determined if using our classic utilities would tend to support or not support the published conclusions. RESULTS: We evaluated 39 articles. Eighteen articles presented results of one-way SAs on utilities. Seven articles presented SAs over a range that included our classic utilities. In 4 of the 7, using classic utilities would change the conclusion of the study. For the 32 articles where no one-way SA were presented (n = 21), or where the classic utilities fell outside the range tested (n =11), a change to classic utility would tend against the study conclusion in 12 articles (31%). CONCLUSIONS: More than a third of published CUA studies could change if pediatric utilities obtained by recommended, classic methods were used. One-way SAs on utilities are often not presented, making comparison between studies challenging.
引用
收藏
页码:219 / 228
页数:10
相关论文
共 50 条
  • [31] Ambrisentan for in pediatric pulmonary arterial hypertension: A cost-utility analysis
    Buendia, Jefferson A.
    Patino, Diana G.
    Lindarte, Erika F.
    PEDIATRIC PULMONOLOGY, 2023, 58 (05) : 1562 - 1568
  • [32] QUALITY OF PEDIATRIC COST-UTILITY ANALYSES 1997-2009
    Ungar, W.
    Kromm, S.
    Bethell, J.
    Kraglund, F.
    Edwards, S.
    Laporte, A.
    Coyte, P.
    VALUE IN HEALTH, 2012, 15 (04) : A195 - A195
  • [33] Cost-utility and cost-benefit analysis of pediatric PCV programs in Egypt
    Sevilla, J. P.
    Burnes, Daria
    El Saie, Rehab Zakaria
    Haridy, Hammam
    Wasserman, Matt
    Pugh, Sarah
    Perdrizet, Johnna
    Bloom, David
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2022, 18 (06)
  • [34] Cost-utility analysis
    Brown, GC
    Brown, MM
    Sharma, S
    ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) : 625 - 626
  • [35] EVIDENCE MAP OF COST-UTILITY MODELS IN MULTIPLE SCLEROSIS PUBLISHED SINCE 1960
    Martin, A.
    VALUE IN HEALTH, 2017, 20 (05) : A194 - A194
  • [36] COST-UTILITY ANALYSIS
    NICHOLLS, A
    BRITISH MEDICAL JOURNAL, 1993, 307 (6913): : 1213 - 1213
  • [37] Primary prevention of pediatric abusive head trauma: A cost audit and cost-utility analysis
    Friedman, Joshua
    Reed, Peter
    Sharplin, Peter
    Kelly, Patrick
    CHILD ABUSE & NEGLECT, 2012, 36 (11-12) : 760 - 770
  • [38] Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis
    Jefferson Antonio Buendía
    Diana Guerrero Patiño
    Erika Fernanda Lindarte
    BMC Pulmonary Medicine, 22
  • [39] Wearable cardioverter-defibrillators in pediatric cardiomyopathy: A cost-utility analysis
    Evers, Patrick D.
    Anderson, Jeffrey B.
    Ryan, Thomas D.
    Czosek, Richard J.
    Knilans, Timothy K.
    Spar, David S.
    HEART RHYTHM, 2020, 17 (02) : 287 - 293
  • [40] Podotimod in pediatric recurrent respiratory tract infections: a cost-utility analysis
    Antonio Buendia, Jefferson
    Guerrero Patino, Diana
    Fernanda Lindarte, Erika
    BMC PULMONARY MEDICINE, 2022, 22 (01)